Published in final edited form as:

J Med Chem. 2009 December 10; 52(23): 7836–7846. doi:10.1021/jm900850t.

Discovery of Potent and Selective Histone Deacetylase Inhibitors via Focused Combinatorial Libraries of Cyclic $\alpha_3\beta$ -Tetrapeptides

Christian A. Olsen and M. Reza Ghadiri*

Department of Chemistry and The Skaggs Institute for Chemical Biology, The Scripps Research Institute, 10550 North Torrey Pines Road, La Jolla, CA 92037 (USA)

Abstract

Histone deacetylase (HDAC) inhibitors are powerful tools in understanding epigenetic regulation and have proven especially promising for the treatment of various cancers, but the discovery of potent, isoform-selective HDAC inhibitors has been a major challenge. We recently developed a cyclic $\alpha_3\beta$ -tetrapeptide scaffold for the preparation of HDAC inhibitors with novel selectivity profiles [Montero, A.; Beierle, J. M.; Olsen, C. A.; Ghadiri, M. R. *J. Am. Chem. Soc.* **2009**, *131*, 3033]. In this study, we elaborate this scaffold with respect to side chain diversity by synthesizing *one-bead-one-compound* combinatorial libraries of cyclic tetrapeptide analogs and applying two generations of these focused libraries to the discovery of potent HDAC ligands using a convenient screening platform. Our studies led to the first HDAC6-selective cyclic tetrapeptide analog, which extends the use of cyclic tetrapeptides to the class-II HDAC isoforms. These findings highlight the persistent potential of cyclic tetrapeptides as epigenetic modulators and possible anticancer-drug lead compounds.

Keywords

Histone deacetylase inhibitors; isoform selectivity; cyclic tetrapeptides; β -amino acids; combinatorial chemistry

Introduction

Histone deacetylases (HDACs^a) are a family of enzymes found in bacteria, fungi, plants, and animals that profoundly affect cellular function. The natural substrates of most HDACs are believed to be *N*^ε-acetyl lysine residues in the tails of histones H2A, H2B, H3 and H4 [supporting information (SI) Figure S1]. The degree of acetylation of these sites affect the packing of nucleosomes in chromatin complexes as well as the recruitment of transcription activator- and repressor-proteins to histone tails, which in turn modulate the extent of gene transcription.^{1–4} The HDAC enzymes are not restricted to deacetylation of histones, however,

*To whom correspondence should be addressed. Department of Chemistry and The Skaggs Institute for Chemical Biology, The Scripps Research Institute, 10550 North Torrey Pines Road, La Jolla, CA 92037 (USA). Fax: (+1) 858-784-2798. ghadiri@scripps.edu.

Supporting Information Available: Figures S1–S7 and ¹H NMR spectra for selected compounds. This material is available free of charge via the Internet at <http://pubs.acs.org>.

^a**Abbreviations:** AMC, 7-amino-4-methylcoumarin; Aoda, (*S*)-2-amino-8-oxo-decanoic acid; Asu, (*S*)-2-amino-suberic acid; DIC, *N,N'*-diisopropylcarbodiimide; FBS, fetal bovine serum; HATU, 2- (1*H*-azabenzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate; HDAC, histone deacetylase; HDLP, HDAC-like protein; HPLC, high performance liquid chromatography; MALDI-TOF, matrix-assisted laser desorption/ionization time-of-flight; MS, mass spectrometry; NAD, nicotinamide adenine dinucleotide; Nal, 1-naphthylalanine; NCoR2, nuclear co-receptor 2; NMR, nuclear magnetic resonance; Pip, pipecolic acid; PMS, *N*-methyl-dibenzopyrazine methyl sulfate; SAR, structure–activity relationship; SPPS, solid-phase peptide synthesis; SPS, solid-phase synthesis; TSA, trichostatin A; XTT, 3'-[1-(phenylaminocarbonyl)-3,4-tetrazolium]-bis-(4-methoxy-6-nitro)-sulphonic acid.

and are known to regulate the function of other proteins in the cell.⁵ For example, HDAC6 has been associated with deacetylation of α -tubulin⁶ as well as peroxiredoxin I and II,⁷ and has been shown to rescue neurodegeneration in *Drosophila melanogaster*.⁸ To date, eleven Zn²⁺-dependent human HDAC enzymes have been identified and classified according to their sequence similarity [class-I: HDACs 1, 2, 3, and 8; class-IIa: HDACs 4, 5, 7, and 9; class-IIb: HDACs 6 and 10; class-IV: HDAC11]. Class-III HDACs comprise a series of NAD⁺-dependent enzymes (Sirtuins 1–7).

Although the majority of HDAC inhibitors in clinical trials are non-selective,^{9, 10} small-molecule HDAC inhibitors have proven to be promising candidates for therapeutic intervention, especially as tumor suppressors for potential cancer chemotherapies.^{3, 11–15} Indeed, several candidates have advanced to clinical trials⁹ and Vorinostat/SAHA was recently approved by the FDA for the treatment of cutaneous T-cell lymphoma.¹⁶ Non-selective HDAC inhibitors have also recently been shown to elicit positive effects related to neurological disorders.^{17–20} Despite these successes with non-selective HDAC inhibitors, the ability to *selectively* perturb individual HDACs with small molecules would be exceedingly useful in unravelling the complex and highly dynamic network of HDAC signaling and in the design of new and safer drug candidates. However, structure-based efforts to design class- or isoform-selective inhibitors have been hampered by the limited structural information available, which currently comprise cocrystal structures of “HDAC-Like Protein” (HDLP),²¹ HDAC8,^{22, 23} and the catalytic domain of HDAC7²⁴ with TSA as well as the catalytic domain of HDAC4.²⁵ Although the class-IIa HDACs have considerably lower intrinsic deacetylase activity compared to class-I HDACs against standard substrates,^{4, 26–28} class-IIa HDACs play pivotal roles in numerous pathways, and they are therefore equally important targets for future selective therapeutic intervention in various diseases.^{4, 29–32}

Nature provides a number of related cyclic scaffolds with HDAC inhibitory activity, including non-ribosomal desipeptides,³³ the recently reported marine natural product largazole,^{34–39} and tetrapeptide natural products such as the trapoxins,^{40, 41} HC toxins,^{42, 43} chlamydocin,⁴³ apicidins (**1**),^{44–46} and the azumamides (**2**)^{47–51} (Figure 1). Numerous analogs of these natural compounds have been investigated as well.^{52–63} For the medicinal chemist, cyclic tetrapeptides built from all α -amino acids often present significant challenges as drug targets due to poor macrolactamization yields for closing the 12-membered ring and multiple three-dimensional conformations on the NMR time scale.^{64–66} We were recently able to minimize these shortcomings by developing synthetic HDAC inhibitor scaffolds (**3**; Figure 1) that have an $\alpha \rightarrow \beta$ -amino acid substitution in the backbone to give a 13-membered ring.⁶⁷ By systematically changing the chirality of the amino acids and the position of the β -amino acid we optimized the scaffold for inhibition of HeLa extract HDAC activity. Moreover, we correlated compound potencies with their high-resolution NMR structures, which allowed us to construct a three-dimensional pharmacophore model. In our previous study, the identities of the side chains were fixed so that we could focus on understanding the effects of peptide backbone modifications on structure and potency. In contrast, here we investigate a variety of side chain functionalities by designing and carrying out total solid-phase synthesis (SPS) of *one-bead-one-compound* libraries⁶⁸ of cyclic peptides for the purpose of inhibiting HDAC enzymes. The present study focuses on HDACs with potent deacetylase activity against histones and standard substrates, i.e., class-I HDACs 1, 3, and 8 as well as class-IIb HDAC6. HDAC2 was omitted from this investigation due to the high degree of sequence similarity to HDAC1.

Results and Discussion

Preliminary SAR Information

To guide the design of the first-generation library, we first surveyed the effect of the Zn²⁺-coordinating group and its distance from the peptide core on our selection of HDAC enzymes.

Although we had previously established that changing the Zn^{2+} -coordinating functionality in peptides **3a–c** accommodated leaps in potency using HeLa cell nuclear extract,⁶⁷ we wished to determine more specifically how the inhibitors acted against the individual HDAC isoforms. We therefore tested **3a–c** against our panel of recombinant human HDACs as well as against a HeLa cell cytosolic extract (Table 1). The inhibition trend described previously for **3a–c** against HeLa nuclear extract (hydroxamic acid > ethylketone > acid Zn^{2+} -coordinating functionality) was also observed for the cytosolic extract as well as HDACs 1 and 3. The IC_{50} values indicated that the predominant source of HDAC activity in HeLa nuclear extract is HDAC1, while HDAC3 seems to be more dominant in HeLa cytosolic extract, which corresponds well with the fact that HDAC3 is known to shuttle into the cytoplasm.⁶⁹ Furthermore, the observed IC_{50} values indicated that the requirements for inhibition of HDAC8 are different from the other HDACs in class-I, in agreement with previous findings.^{10, 22, 23} Interestingly, the ketone **3b**, like apicidin, did not inhibit HDAC6 in the concentration range tested, while acid **3a** proved to be a micromolar inhibitor of HDAC6. This might be explained by an interaction between the carboxylate of **3a** and a free binding site His in HDAC6 (Figure S2). For comparison, HDAC8 contains an active site His residue (His143) that forms a contact with an adjacent Asp (Asp183). Although HDAC6 does contain a corresponding active site His residue, the corresponding Asp is absent, so it is possible that the active site His in HDAC6 is free to interact with the carboxylate in **3a** (Figure S2). This finding was encouraging, since the carboxylic acid Zn^{2+} -coordinating group would provide a useful handle for resin anchoring to synthesize focused libraries of inhibitors via efficient and robust chemical SPS techniques.

To reduce the synthetic effort required for assessing the effect of different lengths of the Zn^{2+} -coordinating side chain, we designed a series of alkylated cysteine-derived analogs (**4a–d**), which enabled evaluation of the distance requirements for the different enzyme isoforms (Figure 1 and Figure S3). The use of alkylated cysteine containing compounds has precedence in the literature for probing HDACs.^{70,71} It was previously shown that changing the linker length by plus/minus one methylene unit significantly decreased the potency of inhibition of HDAC activity in HeLa cell extract;⁵² however, the effect on individual HDAC isoforms was not investigated in that study. Furthermore, largazole analogs with different linker lengths have recently been investigated.⁶¹ With the sulphur atom in compound **4a** extending the linker length by only ~0.28 Å compared to the methylene in **3b** it was not surprising to find that this compound behaved similarly to **3b**. The corresponding compound with a linker of one fewer methylene unit, **4b**, showed total loss of activity. Likewise, the shortened linkers in the carboxylic acids **4c** and **4d** also rendered these peptides less potent than their parent compound (**3a**) across our selection of enzymes. It may be noted, however, that a comparison of compounds **3a** vs. **4c** reveals a ~40-fold decrease in potency against HDAC1 and only a ~3-fold decrease against HDAC8. The length of the linker may thus be a factor to consider when designing isoform selective HDAC ligands. The design of so-called “linker-less” hydroxamic acid HDAC inhibitors with selectivity for HDAC8 was recently reported,⁷² supporting the suggestion that shortened linkers might prove effective against this isoform. Partial decomposition of these thioether compounds was observed upon prolonged storage (presumably due to oxidation of the thioether); nonetheless, they are useful as a discovery tool giving easy access to a variety different linker lengths and Zn^{2+} -coordinating moieties.

First Generation Library Design

Our first-generation library comprised a focused 252-member *one-bead–one-compound* library aimed at exploring the importance of the side chain functionalities for potent HDAC inhibition. Based on our preliminary studies and to facilitate solid phase synthesis, we opted to employ the carboxylic acid Zn^{2+} -coordinating residue for this library. Albeit not the most potent Zn^{2+} -coordinating moiety, the carboxylic acid was considered more appropriate than the hydroxamic acid, since the latter gave rise to poor isoform selectivity for the cyclic

tetrapeptides tested.⁵² The ethylketone containing ligands seemed ideal for inhibition of class-I HDACs 1–3, but showed no inhibitory activity against HDAC6, and the total solid-phase synthetic route to give the ethylketone containing ligands required post cleavage purification (Figure S4), which was not ideal for a high-throughput library screening scheme.

Previous SAR studies involving cyclic tetrapeptides as HDAC inhibitors have indicated that the aromatic residue vicinal to the Zn²⁺-coordinating amino acid (position aa2 in Figure 2) is important for potent inhibition.^{58, 59} We therefore decided to probe this position extensively in our initial library. Aromatic residues of varied bulkiness and polarity as well as non-aromatic hydrophobic residues were included. For position aa3, four different β^3 -amino acids were chosen, including a β^3 -Phe residue to mimic the Phe side chain found in trapoxin and chlamydocin. Residues commonly found in natural product HDAC inhibitors (e.g., Aib, D-Pip, Pro, and Val) were included along with Phe at position aa4. To synthesize the library, the first residue (*N*-Fmoc-(*S*)-Asu-O-Allyl) was anchored to a macrobead 2-chlorotriptyl solid support via its carboxylic acid side chain using protocols previously described developed for regular SPS resins.^{67, 73} The choice of macrobeads as solid support afforded facile handling during the split–pool synthesis procedure and enabled an economical small-scale preparation of each compound while still affording enough material to test each product in several assays in 96-well microtiter plates (Figure 2). After the total synthesis of the 252-member library of ligands including on-resin cyclization, individual beads were arrayed in 96-well plates, cleaved by treatment with a TFA containing cocktail, and dissolved in DMSO to give stock solutions. After screening the library for HDAC inhibitory activity using HeLa nuclear extract, the obtained hits were analyzed and sequenced using an LC-MS/MS procedure previously developed in our lab.⁷⁴

From the initial screen and retesting of the first-generation library for inhibition of HDAC activity in HeLa cell extract, we obtained eight confirmed hits (six different structures) as shown in Figure 3A. Semi-logarithmic plots were obtained from the inhibition data at two different dilutions of the initial stock solutions, from which approximate IC₅₀ values for these peptides were calculated using GraphPad Prism. Interestingly, the two most potent compounds (**8a** and **13**) closely resembled our parent compound (**3a**), having only a single substitution in the aromatic residue at the aa2 site (Trp→naphthylalanine in **8a** or Trp→Phe in **13**). Furthermore, one of the hits with intermediate potency (compound **12**) contained both the aa2–Trp and the aa4–D-Pip residues as found in the natural product apicidin A (**1b**). The abundance of the various side chains by position on the scaffold (Figure 3B) revealed that the aa2 position required an aromatic side chain as anticipated; the naphthylalanine residue, which is similar to Trp in size, was the most abundant in the hit series. At position aa3 the β^3 Leu residue was more abundant than the aromatic residues included in the library, and at position aa4 no consensus could be derived, indicating that the identity of the side chain at this position is less significant for inhibition of HeLa cell HDAC activity.

To confirm the results from the library screening, the four identified naphthylalanine containing compounds (**8a**, **9–11**) were resynthesized on ~50 μ mol scale, purified, and retested to obtain IC₅₀ values against HeLa nuclear extract (Table 2). Their IC₅₀ values confirmed the approximated values from the initial screening data, supporting that the library screening format is appropriate for the discovery of novel HDAC inhibitors. To derive more detailed SAR information from this initial hit series, compound **14** was also prepared along with the ethylketone analog (**8b**) of compound **8a** (Figure S5 and Table 2). The unnatural naphthylalanine residue was confirmed to be a good alternative to Trp at position aa2. Furthermore, the relative IC₅₀ values for carboxylic acid (**8a**) vs ethylketone (**8b**) showed the expected trend, as ethylketone **8b** was 10–30-fold more potent against HeLa extract and HDACs 1 and 3. A decrease in potency was observed for HDAC6, providing further evidence that ketones are not favorable for inhibition of this enzyme isoform. The SAR also suggested

that aromatic side chains at position aa3 are not favorable for inhibition of class-I HDACs (**9** vs **10** and **11** vs **14**). Interestingly, compound **10** was two-fold more potent against HDAC1 compared to our parent carboxylic acid (**3a**) and was somewhat less potent against HDAC3, thus providing a ~10-fold selectivity index for HDAC1 vs HDAC3 as well as potent inhibition of HDAC1 (68 nM). The substitution of the Ala→Phe residue in position aa4 may therefore give rise to an increased selectivity for HDAC1.

Compounds **15** and **16**, in which the least structurally restrictive residue (aa4) was substituted with *N*^ε-Ac-lysine or Aoda, respectively, were also prepared and tested (Table 2) so that we could ascertain how such substitutions would influence binding to the HDACs before designing a second-generation library. The Lys(Ac)-aa4 residue in compound **15** was inspired by the two consecutive lysine residues K381 and K382 known to be involved in acetylation/deacetylation events in the transcription factor p53. Moreover, the Lys(Ac)-Lys(Ac) motif has been used in a commercially available fluorescent HDAC8 substrate [His-Arg-Lys(Ac)-Lys(Ac)-AMC, www.biomol.com], which led us to hypothesize that such a motif might provide an improved degree of recognition by HDAC8. The Aoda-Aoda sequence in **16** provides a double isosteric version of this feature. Indeed, improved activity against HDAC8 was observed for compound **15** (150 nM) and to a much lesser extent for **16** (1,400 nM); however, the IC₅₀ values for inhibition of HDACs 1 and 3 were still in the same range as observed for parent compounds **3b** and apicidin (Table 2).

Second Generation Library Design, Synthesis, and Screening

Based on the SAR information gathered from the first generation library, we decided to focus on the diversification of the aa3 and aa4 positions in the second-generation library in the hopes of reducing bias for class-I HDAC inhibitory activity. In addition to amino acids found in the various non-ribosomal cyclic tetrapeptide inhibitors and their analogs (mostly hydrophobic residues), a number of hydrophilic residues (i.e., β³Ser, Thr, Arg, and Lys) were included due to the presence of these side chains in the histone tails (Figure S1). Aspartic acid was also included due to its presence vicinal to an *N*^ε-acetylated lysine in α-tubulin, which is known to be a substrate for HDAC6.

A 525-member second-generation library (Figure 4) was next synthesized on macrobeads as described for the initial library. The compounds were initially screened for HDAC inhibition activity in HeLa cell extract, and then both libraries were counter-screened against HDAC6. As before, the hits were confirmed by retesting the stock solutions in duplicate as well as performing LC-MS/MS sequencing and MALDI-TOF MS, which furnished another nine hit structures (for full hit series, see Figure S6 and Figure S7). All the hits contained either Trp or naphthylalanine at the aa2 position. In addition to the results already discussed for the first generation library above, Tyr at the aa3 position was observed in a number of hits, while Phe (F₅) or Arg appeared at the aa4 position. Unfortunately, no hits against HDAC6 were observed that were not also inhibitors of HeLa HDAC activity. Three peptides that were hits against both HeLa extract and HDAC6, all of which had an Arg residue at the aa4 position, were resynthesized (compounds **17–19**) along with two analogs having either a Phe(F₅) or a Lys(Ac) residue at the aa4 position, respectively (compounds **20, 21**) [Figure 5 and Table 2]. The obtained IC₅₀ values revealed that the unnatural Phe(F₅) residue, which was present in a number of hits from the HeLa HDAC activity screening, resulted in low potency of compound **21** over the whole selection of enzyme isoforms tested, so other hit structures containing this residue were not pursued further.

Structure–Activity Relationships and HDAC Isoform Selectivity

The compounds differing only in the identity of the residue at position aa3 (**17–19**) revealed interesting SAR information. Notably, the compound having the β³Tyr–Arg motif at positions

aa3–aa4 (**19**) was the most potent carboxylic acid-containing inhibitor of HDAC6 identified so far, and had also the best selectivity index (HDAC3/HDAC6 = 0.65) in the series, albeit still in favor of the class-I HDACs. Since HDAC6 is known to deacetylate α -tubulin, we decided to combine the β^3 Tyr–Arg motif with an Asp residue at the aa2 position to give compounds **22** and **23**. Interestingly, a successful reversal of the isoform selectivity pattern was achieved with compound **23**, as the selectivity indices for HDAC1/HDAC6, HDAC3/HDAC6, and HDAC8/HDAC6 were approximately 3, 4, and 6, respectively, with potent inhibition of HDAC6 (IC_{50} = 39 nM). Compound **23** is, to the best of our knowledge, the first cyclic tetrapeptide analog exhibiting isoform selectivity toward a class-II HDAC. Moreover, its selectivity index is comparable to that observed for tubacin (HDAC1/HDAC6 selectivity index of 7),^{75–77} and its potency is in the nanomolar range as recently reported for a series of thiolate containing inhibitors^{78, 79} inspired by an HDAC6 selective substrate.^{80, 81} More potent (picomolar) HDAC6 selective inhibitors containing a phenylisoxazole surface recognition group have also been reported recently.⁸² The ethylketone analog **24** containing the aa4–Phe residue as observed in compound **10** was prepared in the hopes that higher potency against HDAC1 could be obtained while still retaining the selectivity profile discussed for **10**, but peptide **24** was unfortunately too hydrophobic and hence insoluble under the assay conditions. As expected based on previously observed trends for hydroxamic acid compound **3c**, the hydroxamic acid containing homolog **25** was a potent inhibitor of both classes of HDACs.

To derive more detailed SAR related to compounds **17**, **19**, and **20**, we also prepared peptides **26** and **27** containing the Lys–aa4 and the Lys(Ac)–aa4 residues, respectively. The potencies of these compounds confirm that an aromatic residue at position aa3 results in decreased potency against the class-I HDACs, as previously observed for **9–14**. Furthermore, the results show that substitution of the Lys(Ac)–aa4 residue (**27**) for an Arg–aa4 (**17**) or a Lys–aa4 residue (**26**) had little effect on the inhibitory activities measured against the entire selection of HDACs. It was recently reported that an Arg residue vicinal to the Lys(Ac) promoted binding of synthetic histone substrates to HDAC8,⁸³ which also corresponds well with the observation that most of the lysine residues known to participate in acetylation/deacetylation events in the tails of histones H3, H4, and H2A have Arg residues in their vicinity (Figure S1). Taking into account that compounds **17**, **26**, and **27** are also 4–5 fold more potent against HDAC3 and 3–4 fold more potent against HDAC6 when compared to their Ala–aa4 analog (**8b**), our results suggest that the presence of an Arg residue vicinal to the Zn^{2+} -coordinating amino acid may also promote binding to other HDAC isoforms (i.e., HDACs 3 and 6 in this study). To check if the Lys(Ac) residue in **27** was deacetylated under the conditions of our assay, we carried out the standard HeLa extract assay with this compound (at concentrations of 10 μ M or 1 μ M), but instead of the trypsin development step, we quenched the reaction with MeOH and analyzed the reaction mixtures by LC-MS. These experiments showed the peak expected for compound **27**, but no trace of the corresponding deacetylated analog (**26**).

Finally, the composition of our most potent inhibitor of HDAC8 (compound **15**) was combined with the cysteine derived Zn^{2+} -coordinating amino acid containing one methylene unit fewer than Asu (as in **4c**) to give peptide **28**. Although the HDAC3/HDAC8 selectivity was reversed, the potency against HDAC8 was not considered satisfactory. Efforts to design cyclic tetrapeptide inhibitors with improved potency as well as selectivity for HDAC8 are now in progress in our laboratory. The SAR information obtained is summarized in Figure 6.

Western Blot Analysis and Cell Growth Inhibition

To assess the effectiveness of our novel inhibitors in cells, we treated Jurkat cells (T-cell leukemia) with a selection of compounds (apicidin **1a**, **10**, **15**, and **23**) for 24 hours and western blotted for histone H3, acetylated histone H3 (K9+K14), and acetylated α -tubulin as previously described.⁸⁴ The presence of acetylated tubulin is an indicator of HDAC6 inhibition, whereas

the presence of acetylated histone H3 indicates inhibition of the class-I HDACs. Similarly, as expected based on the IC_{50} values obtained with the recombinant enzyme isoforms, the two ketone containing compounds (apicidin and **15**) exhibited potent histone deacetylase activity and only minor tubulin deacetylase activity. We were also pleased to find that library hit **10**, containing the carboxylic acid Zn^{2+} -coordinating group, affected the acetylated histone levels in the cells compared to the DMSO control, whereas the effect on acetylated α -tubulin levels was considerably less pronounced in relation to the corresponding DMSO control. As expected considering the in vitro enzyme inhibition data, **10** was less potent than both apicidin and **15** (Figure 7). Finally, the HDAC6 selectivity of compound **23** was confirmed by the presence of relatively high levels of acetylated α -tubulin, with comparably low levels of histone H3 acetylation.

Growth inhibition of various cancer cell lines by selected compounds was next determined using the XTT assay (Table 3).^{67, 85} Except for the highly potent hydroxamic-acid-containing broad spectrum HDAC inhibitors (**3c** and **25**), which were also broadly cytotoxic, the general trend seemed to be that cytotoxicity correlated largely with potent HDAC1 inhibition. Our most potent carboxylic acid HDAC inhibitor (**10**) did not potently inhibit the growth in any of our series of cancer cells, which is in accord with the relatively weak inhibition of HDAC activity in Jurkat cells compared to compound **15** and apicidin indicated by the western blot. Interestingly, compound **15**, which is an analog of **3b** with slightly lower potency against HDAC1 (~2-fold) and significantly higher potency against HDAC8 (~15-fold), was less cytotoxic than **3b** towards HeLa cells, indicating that HDAC8 may not be important for cell survival in this cell line. Moreover, compound **23**, which is a >250-fold more potent inhibitor of HDAC6 than **3b** and only ~5-fold less potent against HDAC1, was less cytotoxic towards HeLa cells than **3b**, indicating that HDAC6 is less important than HDAC1 for cell survival. Clearly, these findings require further support, and differences in cell permeability may also play a major role in the different cytoselectivity profiles observed. In Jurkat cells, for example, compound **8b** proved slightly more potent than the hydroxamic acid inhibitor **3c**, even though **3c** is a more potent inhibitor of all the HDACs tested in vitro. This observation may be explained by an expected more favorable logP value for compound **8b**. The trend observed for these compounds against HeLa, K-562, and KYO-1 cells seem to better reflect the HDAC inhibitory activities, confirming that several factors play important roles in the growth inhibition process. Taken together with the western blots, these results show that our compounds may find use as specific small molecule probes to regulate histone and/or tubulin acetylation at sub-cytotoxic concentrations in cells. Finally, we were pleased to find that by reintroducing the strong Zn^{2+} -coordinating hydroxamic acid moiety in one of the hit compounds to give **25**, we were able to obtain potent growth inhibition in a number of cell lines. This provides further evidence that the effects of the cyclic peptide core and the Zn^{2+} -coordinating moiety on potency may be considered somewhat additive in this class of compounds.

Conclusions

A synthetic tetrapeptide scaffold having an $\alpha \rightarrow \beta$ -amino acid substitution in the backbone has been employed for the identification of moderately selective inhibitors for the HDAC isoforms 1 and 6. Using an all (*S*)-configured $\alpha_3\beta$ ring type as the lead compound, a semi-high-throughput screening scheme was developed for assaying ligands from focused *one-bead-one-compound* libraries. The present study shows that this screening platform in combination with structural information from natural as well as synthetic HDAC substrates and inhibitors is useful for the discovery of new HDAC inhibitors. The obtained SAR information revealed a range of potent compounds displaying novel side chain patterns and containing unnatural amino acid residues. Depending on the HDAC isoform in question, different amino acid positions on the scaffold proved more or less important for potency, which will aid the future

design of selective ligands, help identify optimal sites for labeling, and enable the design of efficient probes for activity-based proteomics or affinity matrix pull down studies.^{41, 86, 87}

Our data also indicate that the cyclic tetrapeptide motif not only provides a highly modular scaffold, but also that this class of compounds can be further modulated by changing the Zn^{2+} -coordinating moiety in order to finetune potency, HDAC isoform selectivity, or cytoselectivity. Importantly, compounds exhibiting potent HDAC inhibitory activity and isoform selectivity were identified and shown to work in cell culture. It is remarkable that from this relatively small selection of compounds it was possible to design ligands with completely reversed selectivity profiles as compared to the known natural product tetrapeptide inhibitors. We therefore envision that this discovery platform may find additional use for the design of class- and isoform-selective HDAC inhibitors targeting other enzyme isoforms. It will be interesting to explore trends in cytoselectivity between different cell lines in greater detail with these ligands, because such studies will help delineate the significance of individual HDACs in various cancers. This knowledge may aid the design of targeted drug candidates with lower toxicity and fewer side effects.

Experimental Section

Enzymes and Chemicals

HDAC1, HDAC3–NCoR2, HDAC6, and HDAC8 were purchased from BPS Biosciences (San Diego, CA). Trypsin (TPCK treated, from bovine pancreas; 12,500 units/mg) was from Sigma-Aldrich (Milwaukee, WI). 2-Cl-trityl chloride resin macrobeads were from Peptides International (Louisville, KY), Weinreb amide resin was from Novabiochem (San Diego, CA), and 2-chlorotrityl *N*-Fmoc-hydroxylamine resin was from Sigma-Aldrich (Milwaukee, WI). β -Amino acids were purchased from Peptech Corporation (Burlington, MA). All α -amino acids, chemicals, and solvents were used as received from suppliers. HDAC assay buffer was prepared as described in the Biomol International protocol AK-503 [Tris/Cl (50 mM), NaCl (137 mM), KCl (2.7 mM), MgCl_2 (1 mM), pH 8.0]. Histone H3 antibody was from Abcam (Cambridge, MA), acetylated K9+K14 histone antibody was from Upstate (Temecula, CA), and acetylated α -tubulin antibody was from Sigma (St. Louis, MO).

Library Synthesis

N-Fmoc-(*S*)-2-Asu(*t*-Bu)-Oallyl (3 equiv with respect to the resin) was stirred in TFA– CH_2Cl_2 for 1 h,⁷³ the solvents were evaporated in vacuo, and the residue was co-evaporated several times with CH_2Cl_2 –hexane and dried for 2 h under high vacuum. The TFA-free residue was taken up in CH_2Cl_2 (2 mL/100 mg) and *i*-Pr₂EtN (20 equiv), and was shaken with 2-Cl-trityl chloride macrobeads in a fritted syringe for 16 h. The resin was washed with DMF, MeOH, and CH_2Cl_2 (3× each), and the loading was determined by UV measurement (290 nm) of the chromophore in an Fmoc deprotected sample (Novabiochem procedure). The bulk of the resin was then Fmoc deprotected with DMF–piperidine (3:1, 2× 20 min), washed with DMF, MeOH, and CH_2Cl_2 (3× each), and dried in vacuo. Three cycles of combinatorial split–pool Fmoc peptide synthesis were then performed in 3 mL fritted syringes, applying the Fmoc protected amino acids (5 equiv), DIC (5 equiv), HOBt (5 equiv), and bromophenol blue (2 equiv) as internal indicator in each coupling step.⁸⁸ Standard Fmoc deprotection and washing protocols were applied. After coupling of the fourth amino acid, the resins were washed with DMF, MeOH, CH_2Cl_2 , and CHCl_3 –*N*-methylmorpholine degassed with argon (3× each). The allyl group was then cleaved with $\text{Pd}(\text{Ph}_3\text{P})_4$ (0.2 equiv) in degassed CHCl_3 –*N*-methylmorpholine (4 mL) by shaking for 16 h in the dark, after which time the resin was washed with DMF, 1% sodium dimethylthiocarbamate in DMF, and then neat DMF again (2× each), followed by Fmoc deprotection and standard washing. Finally, the resin-bound peptides were cyclized (2× 12 h) with HATU (5 equiv) and *i*-PrEt₂N (20 equiv) in DMF (3 mL), washed extensively, and dried

under high vacuum. The beads were then divided into individual wells in round-bottomed 96-well polypropylene microtiter plates (Fisherbrand), leaving a column free for the standards and controls during screening. To each well was added ~200 μL of a cleavage cocktail [TFA– CH_2Cl_2 – $i\text{-Pr}_3\text{SiH}$ – H_2O (48:48:2:2)] and the plates were left for 16 h. Residual solvents were removed by placing the plates under vacuum in a desiccator for 24 h, before DMSO was added to give stock solutions (1 mM theoretical concentration based on the initial loading and beads/mg) of each peptide for screening and sequencing.

Peptide Synthesis

Compounds were prepared on solid phase with cyclization on the resin (for hydroxamic acids) or in solution (for ethylketones) as previously described.⁶⁷ Linear precursors for carboxylic-acid-containing pseudopeptides were prepared by standard Fmoc SPPS and cleaved using 2,2,2-trifluoroethanol–HOAc– CH_2Cl_2 (2:2:6) in order to keep the side chain protecting groups in place until after cyclization in solution. All compounds were purified to homogeneity by preparative reversed-phase HPLC (C-18 column) and the obtained fractions were lyophilized to give the compounds as fluffy solids that were characterized by LC-MS and high resolution ESI-TOF MS (Table 4) as well as ^1H NMR for selected compounds. The purities of the compounds were determined by analytical HPLC with UV detection at 230 nm, using a Phenomenex Luna 150 $\times$ 4.6 mm C18(2) column (5 μ) eluted at a rate of 1.5 mL/min. Injection volumes were 20 μL of approximately 1 mg/mL solution. The gradient elution system consisted of eluent A (H_2O –MeCN–TFA 99:1:0.1) and eluent B (MeCN– H_2O –TFA 90:10:0.07) rising linearly from 0% to 100% of B during 30 min. All cyclic peptides were $\geq 95\%$ pure, with the exceptions of compounds **4d**, **9**, **23**, and **27**, which were $\geq 90\%$ pure. The HPLC purity of each compound is given in Table 4. DMSO stock solutions were prepared using UV [$\epsilon(\text{Trp}) = 5690 \text{ M}^{-1} \times \text{cm}^{-1}$ (280 nm) and $\epsilon(\text{Tyr}) = 1280 \text{ M}^{-1} \times \text{cm}^{-1}$ (280 nm)] to adjust the concentrations. Stock solutions of compounds lacking these aromatic chromophores were prepared by weight.

IC₅₀ Determination

The IC₅₀ values against HeLa extracts were determined using the standard Biomol HDAC fluorimetric assay protocol (AK-503).⁸⁵ For inhibition of recombinant human HDACs the dose–response experiments with internal controls were performed in black or white low binding NUNC 96-well microtiter plates. The dilution series were prepared in Milli-Q water from 1 mM DMSO stock solutions. The appropriate dilution of the inhibitor (10 μL of a 5 $\times$ concentration solution) was added to each well followed by HDAC assay buffer (37.5 μL) containing Ac-Lys(Ac)-AMC substrate (67 μM) and bovine serum albumin (0.75 mg/mL). For HDAC8 the Arg-His-Lys(Ac)-Lys(Ac)-AMC substrate (27 μM) was used. Finally, a solution of the appropriate HDAC (2.5 μL) was added and the plate was incubated at 37 °C for 30 min in the dark [HDAC1, 0.09 $\mu\text{g}/\mu\text{L}$; HDAC3, 0.03 $\mu\text{g}/\mu\text{L}$; HDAC6, 0.011 $\mu\text{g}/\mu\text{L}$; HDAC8, 0.4 $\mu\text{g}/\mu\text{L}$]. Then trypsin (50 μL , 0.4 mg/mL) was added and the assay development was allowed to proceed for 15 min at RT, before the plate was read using a Tecan GENios plate reader with excitation at 360 nm and detecting emission at 460 nm.

Library Screening and Hit Identification

Dilutions of 10 μM and 1 μM were prepared from each of the 1 mM DMSO stock solutions, and 10 μL of each were added to white NUNC assay plates. In each plate, standards and controls consisted of duplicate wells of: 1) no enzyme (blank); 2) 1 μM of inhibitor **3a**; 3) 1 μM of apicidin; or 4) no inhibitor (max read-out) were installed in each plate. For screening of HDAC6 we used TSA (0.1 μM) instead of apicidin as one of the internal standards. Each plate was assayed as described above for the purified peptides, and compounds that were considered hits, i.e., satisfied our criteria for inhibition at both concentrations, were rediluted and retested in duplicate to weed out false positives. Hits that also satisfied this round of screening were then

sequenced using automated LC–MS/MS as previously described,^{74, 89–91} and parent ion masses were confirmed by either negative mode sonic spray ionization (SSI) MS or MALDI-TOF MS.

Western Blot Analysis

Jurkat cells were cultivated in RPMI 1640 medium supplemented with 10% fetal bovine serum and antibiotics. At confluency, cells were seeded in six-well plates and incubated with various concentrations of the inhibitor compounds at 37 °C for 24 h. The cells were then washed, harvested, and lysed. The lysates were run on 4–12% polyacrylamide SDS page gels (Invitrogen), transferred to nitrocellulose membranes, and visualized as described previously.⁸⁴ TSA and the vehicle (DMSO) were used as positive and negative controls, respectively.

Cancer Cell Cytotoxicity Assays

Cells were cultivated in flat 96-well tissue culture plates in 90 µL of medium supplemented with 10% FBS and antibiotics. HeLa cells were seeded at a density of 5,000 cells/well, Jurkat and MCF-7 at a density of 10,000 cells/well, and K-562 and KYO-1 at a density of 15,000 cells/well. Twenty-four hours later, 10 µL of medium containing various concentrations of the desired compounds were added in triplicate, and the cells were incubated at 37 °C for 72 h in a 5% CO atmosphere. Cell survival was determined using the XTT (Sigma-aldrich, St. Louis, MO) colorimetric assay. Immediately prior to use, a mixture of XTT (1 mg/mL) and PMS (*N*-methyl dibenzopyrazine methyl sulfate, 0.383 mg/mL) in phenol red free RPMI was prepared (0.1 mL of PMS per 5 mL of XTT solution). After adding 50 µL of this mixture to each well, plates were incubated at 37 °C for 2 h in the case of HeLa and MCF-7 cells, and 4 h for Jurkat, K-562, and KYO-1 cells. Plates were shaken to evenly distribute the dye in the wells and the absorbance was measured using a Tecan GENios plate reader spectrometer at a wavelength of 485 nm.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

We thank the TSRI Mass Spectrometry Facility for high resolution mass spectral analyses, Dr. Ana Montero for cell lines and HeLa cell extracts, Mr. Andrei Loutchnikov and Mr. Devon Cayer for MCF-7 and Jurkat cell lines, respectively, Prof. Joel M. Gottesfeld, Dr. James C. Chou, and Dr. David Herman for helpful discussions and assistance with western blot analyses, as well as Dr. Luke J. Leman for fruitful discussions and invaluable comments on this manuscript. C.A.O. thanks the Benzon Foundation and the Lundbeck Foundation for postdoctoral fellowships as well as the Danish Independent Research Council for a Young Researcher's Award (274-06-0317). This work was supported in part by a grant from the National Institute of General Medical Sciences (GM52190) and the Skaggs Institute for Chemical Biology.

References

1. Kouzarides T. Chromatin modifications and their function. *Cell* 2007;128:693–705. [PubMed: 17320507]
2. Allis CD, Berger SL, Cote J, Dent S, Jenuwien T, Kouzarides T, Pillus L, Reinberg D, Shi Y, Shiekhhattar R, Shilatifard A, Workman J, Zhang Y. New nomenclature for chromatin-modifying enzymes. *Cell* 2007;131:633–636. [PubMed: 18022353]
3. Biel M, Wascholowski V, Giannis A. Epigenetics-an epicenter of gene regulation: histones and histone-modifying enzymes. *Angew Chem Int Ed* 2005;44:3186–3216.
4. Verdin E, Dequiedt F, Kasler HG. Class II histone deacetylases: versatile regulators. *Trends Genet* 2003;19:286–293. [PubMed: 12711221]

5. Yuan ZL, Guan YJ, Chatterjee D, Chin YE. Stat3 dimerization regulated by reversible acetylation of a single lysine residue. *Science* 2005;307:269–273. [PubMed: 15653507]
6. Hubbert C, Guardiola A, Shao R, Kawaguchi Y, Ito A, Nixon A, Yoshida M, Wang XF, Yao TP. HDAC6 is a microtubule-associated deacetylase. *Nature* 2002;417:455–458. [PubMed: 12024216]
7. Parmigiani RB, Xu WS, Venta-Perez G, Erdjument-Bromage H, Yaneva M, Tempst P, Marks PA. HDAC6 is a specific deacetylase of peroxiredoxins and is involved in redox regulation. *Proc Natl Acad Sci U S A* 2008;105:9633–9638. [PubMed: 18606987]
8. Pandey UB, Nie Z, Batlevi Y, McCray BA, Ritson GP, Nedelsky NB, Schwartz SL, DiProspero NA, Knight MA, Schuldiner O, Padmanabhan R, Hild M, Berry DL, Garza D, Hubbert CC, Yao TP, Baehrecke EH, Taylor JP. HDAC6 rescues neurodegeneration and provides an essential link between autophagy and the UPS. *Nature* 2007;447:859–863. [PubMed: 17568747]
9. Paris M, Porcelloni M, Binaschi M, Fattori D. Histone deacetylase inhibitors: from bench to clinic. *J Med Chem* 2008;51:1505–1529. [PubMed: 18247554]
10. Bieliauskas AV, Pflum MK. Isoform-selective histone deacetylase inhibitors. *Chem Soc Rev* 2008;37:1402–1413. [PubMed: 18568166]
11. Cole PA. Chemical probes for histone-modifying enzymes. *Nat Chem Biol* 2008;4:590–597. [PubMed: 18800048]
12. Bolden JE, Peart MJ, Johnstone RW. Anticancer activities of histone deacetylase inhibitors. *Nat Rev Drug Discov* 2006;5:769–784. [PubMed: 16955068]
13. Minucci S, Pelicci PG. Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. *Nat Rev Cancer* 2006;6:38–51. [PubMed: 16397526]
14. Marks P, Rifkind RA, Richon VM, Breslow R, Miller T, Kelly WK. Histone deacetylases and cancer: causes and therapies. *Nat Rev Cancer* 2001;1:194–202. [PubMed: 11902574]
15. Marks PA, Richon VM, Breslow R, Rifkind RA. Histone deacetylase inhibitors as new cancer drugs. *Curr Opin Oncol* 2001;13:477–483. [PubMed: 11673688]
16. Marks PA, Breslow R. Dimethyl sulfoxide to vorinostat: development of this histone deacetylase inhibitor as an anticancer drug. *Nat Biotechnol* 2007;25:84–90. [PubMed: 17211407]
17. Kazantsev AG, Thompson LM. Therapeutic application of histone deacetylase inhibitors for central nervous system disorders. *Nat Rev Drug Discov* 2008;7:854–868. [PubMed: 18827828]
18. Fischer A, Sananbenesi F, Wang X, Dobbin M, Tsai LH. Recovery of learning and memory is associated with chromatin remodelling. *Nature* 2007;447:178–182. [PubMed: 17468743]
19. Herman D, Jenssen K, Burnett R, Soragni E, Perlman SL, Gottesfeld JM. Histone deacetylase inhibitors reverse gene silencing in Friedreich's ataxia. *Nat Chem Biol* 2006;2:551–558. [PubMed: 16921367]
20. Tsankova NM, Berton O, Renthall W, Kumar A, Neve RL, Nestler EJ. Sustained hippocampal chromatin regulation in a mouse model of depression and antidepressant action. *Nat Neurosci* 2006;9:519–525. [PubMed: 16501568]
21. Finnin MS, Donigian JR, Cohen A, Richon VM, Rifkind RA, Marks PA, Breslow R, Pavletich NP. Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors. *Nature* 1999;401:188–193. [PubMed: 10490031]
22. Somoza JR, Skene RJ, Katz BA, Mol C, Ho JD, Jennings AJ, Luong C, Arvai A, Buggy JJ, Chi E, Tang J, Sang BC, Verner E, Wynands R, Leahy EM, Dougan DR, Snell G, Navre M, Knuth MW, Swanson RV, McRee DE, Tari LW. Structural snapshots of human HDAC8 provide insights into the class I histone deacetylases. *Structure* 2004;12:1325–1334. [PubMed: 15242608]
23. Vannini A, Volpari C, Filocamo G, Casavola EC, Brunetti M, Renzoni D, Chakravarty P, Paolini C, De Francesco R, Gallinari P, Steinkuhler C, Di Marco S. Crystal structure of a eukaryotic zinc-dependent histone deacetylase, human HDAC8, complexed with a hydroxamic acid inhibitor. *Proc Natl Acad Sci U S A* 2004;101:15064–15069. [PubMed: 15477595]
24. Schuetz A, Min J, Allali-Hassani A, Schapira M, Shuen M, Loppnau P, Mazitschek R, Kwiatkowski NP, Lewis TA, Maglathin RL, McLean TH, Bochkarev A, Plotnikov AN, Vedadi M, Arrowsmith CH. Human HDAC7 harbors a class IIa histone deacetylase-specific zinc binding motif and cryptic deacetylase activity. *J Biol Chem* 2008;283:11355–11363. [PubMed: 18285338]
25. Bottomley MJ, Lo Surdo P, Di Giovine P, Cirillo A, Scarpelli R, Ferrigno F, Jones P, Neddermann P, De Francesco R, Steinkuhler C, Gallinari P, Carfi A. Structural and functional analysis of the

- human HDAC4 catalytic domain reveals a regulatory structural zinc-binding domain. *J Biol Chem* 2008;283:26694–26704. [PubMed: 18614528]
26. Fischle W, Dequiedt F, Hendzel MJ, Guenther MG, Lazar MA, Voelter W, Verdin E. Enzymatic activity associated with class II HDACs is dependent on a multiprotein complex containing HDAC3 and SMRT/N-CoR. *Mol Cell* 2002;9:45–57. [PubMed: 11804585]
27. Fischle W, Dequiedt F, Fillion M, Hendzel MJ, Voelter W, Verdin E. Human HDAC7 histone deacetylase activity is associated with HDAC3 in vivo. *J Biol Chem* 2001;276:35826–35835. [PubMed: 11466315]
28. Lahm A, Paolini C, Pallaoro M, Nardi MC, Jones P, Neddermann P, Sambucini S, Bottomley MJ, Lo Surdo P, Carfi A, Koch U, De Francesco R, Steinkuhler C, Gallinari P. Unraveling the hidden catalytic activity of vertebrate class IIa histone deacetylases. *Proc Natl Acad Sci U S A* 2007;104:17335–17340. [PubMed: 17956988]
29. Vega RB, Matsuda K, Oh J, Barbosa AC, Yang X, Meadows E, McAnally J, Pomajzl C, Shelton JM, Richardson JA, Karsenty G, Olson EN. Histone deacetylase 4 controls chondrocyte hypertrophy during skeletogenesis. *Cell* 2004;119:555–566. [PubMed: 15537544]
30. Chang S, Young BD, Li S, Qi X, Richardson JA, Olson EN. Histone deacetylase 7 maintains vascular integrity by repressing matrix metalloproteinase 10. *Cell* 2006;126:321–334. [PubMed: 16873063]
31. Tao R, de Zoeten EF, Ozkaynak E, Chen C, Wang L, Porrett PM, Li B, Turka LA, Olson EN, Greene MI, Wells AD, Hancock WW. Deacetylase inhibition promotes the generation and function of regulatory T cells. *Nat Med* 2007;13:1299–1307. [PubMed: 17922010]
32. Wang S, Li X, Parra M, Verdin E, Bassel-Duby R, Olson EN. Control of endothelial cell proliferation and migration by VEGF signaling to histone deacetylase 7. *Proc Natl Acad Sci U S A* 2008;105:7738–7743. [PubMed: 18509061]
33. Schreiber, SL.; Kapoor, T.; Wess, G., editors. *Chemical Biology: From Small Molecules to Systems Biology and Drug Design*. Vol. 2. 2007. p. 303
34. Taori K, Paul VJ, Luesch H. Structure and activity of largazole, a potent antiproliferative agent from the Floridian marine cyanobacterium *Symploca* sp. *J Am Chem Soc* 2008;130:1806–1807.
35. Ying Y, Taori K, Kim H, Hong J, Luesch H. Total synthesis and molecular target of largazole, a histone deacetylase inhibitor. *J Am Chem Soc* 2008;130:8455–8459. [PubMed: 18507379]
36. Seiser T, Kamena F, Cramer N. Synthesis and biological activity of largazole and derivatives. *Angew Chem Int Ed* 2008;47:6483–6485.
37. Bowers A, West N, Taunton J, Schreiber SL, Bradner JE, Williams RM. Total synthesis and biological mode of action of largazole: a potent class I histone deacetylase inhibitor. *J Am Chem Soc* 2008;130:11219–11222. [PubMed: 18642817]
38. Nasveschuk CG, Ungermannova D, Liu X, Phillips AJ. A concise total synthesis of largazole, solution structure, and some preliminary structure activity relationships. *Org Lett* 2008;10:3595–3598. [PubMed: 18616341]
39. Ghosh AK, Kulkarni S. Enantioselective total synthesis of (+)-largazole, a potent inhibitor of histone deacetylase. *Org Lett* 2008;10:3907–3909. [PubMed: 18662003]
40. Kijima M, Yoshida M, Sugita K, Horinouchi S, Beppu T. Trapoxin, an antitumor cyclic tetrapeptide, is an irreversible inhibitor of mammalian histone deacetylase. *J Biol Chem* 1993;268:22429–22435. [PubMed: 8226751]
41. Taunton J, Hassig CA, Schreiber SL. A mammalian histone deacetylase related to the yeast transcriptional regulator Rpd3p. *Science* 1996;272:408–411. [PubMed: 8602529]
42. Kawai M, Rich DH, Walton JD. The structure and conformation of HC-toxin. *Biochem Biophys Res Commun* 1983;111:398–403. [PubMed: 6132602]
43. Shute RE, Dunlap B, Rich DH. Analogues of the cytostatic and antimetogenic agents chlamydocin and HC-toxin: synthesis and biological activity of chloromethyl ketone and diazomethyl ketone functionalized cyclic tetrapeptides. *J Med Chem* 1987;30:71–78. [PubMed: 3806605]
44. Darkin-Rattray SJ, Gurnett AM, Myers RW, Dulski PM, Crumley TM, Allocco JJ, Cannova C, Meinke PT, Colletti SL, Bednarek MA, Singh SB, Goetz MA, Dombrowski AW, Polishook JD, Schmatz DM. Apicidin: a novel antiprotozoal agent that inhibits parasite histone deacetylase. *Proc Natl Acad Sci U S A* 1996;93:13143–13147. [PubMed: 8917558]

45. Singh SB, Zink DL, Polishook JD, Dombrowski AW, DarkinRattray SJ, Schmatz DM, Goetz MA. Apicidins: Novel cyclic tetrapeptides as coccidiostats and antimalarial agents from *Fusarium pallidoroeseum*. *Tetrahedron Lett* 1996;37:8077–8080.
46. Kranz M, Murray PJ, Taylor S, Upton RJ, Clegg W, Elsegood MR. Solution, solid phase and computational structures of apicidin and its backbone-reduced analogs. *J Pept Sci* 2006;12:383–388. [PubMed: 16342331]
47. Nakao Y, Yoshida S, Matsunaga S, Shindoh N, Terada Y, Nagai K, Yamashita JK, Ganesan A, van Soest RW, Fusetani N. Azumamides A-E: histone deacetylase inhibitory cyclic tetrapeptides from the marine sponge *Mycale izuensis*. *Angew Chem Int Ed* 2006;45:7553–7557.
48. Izzo I, Maulucci N, Bifulco G, De Riccardis F. Total synthesis of azumamides A and E. *Angew Chem Int Ed* 2006;45:7557–7560.
49. Maulucci N, Chini MG, Micco SD, Izzo I, Cafaro E, Russo A, Gallinari P, Paolini C, Nardi MC, Casapullo A, Riccio R, Bifulco G, Riccardis FD. Molecular insights into azumamide E histone deacetylases inhibitory activity. *J Am Chem Soc* 2007;129:3007–3012. [PubMed: 17311384]
50. Wen S, Carey KL, Nakao Y, Fusetani N, Packham G, Ganesan A. Total synthesis of azumamide A and azumamide E, evaluation as histone deacetylase inhibitors, and design of a more potent analogue. *Org Lett* 2007;9:1105–1108. [PubMed: 17311393]
51. Nakao Y, Narazaki G, Hoshino T, Maeda S, Yoshida M, Maejima H, Yamashita JK. Evaluation of antiangiogenic activity of azumamides by the in vitro vascular organization model using mouse induced pluripotent stem (iPS) cells. *Bioorg Med Chem Lett* 2008;18:2982–2984. [PubMed: 18397826]
52. Furumai R, Komatsu Y, Nishino N, Khochbin S, Yoshida M, Horinouchi S. Potent histone deacetylase inhibitors built from trichostatin A and cyclic tetrapeptide antibiotics including trapoxin. *Proc Natl Acad Sci U S A* 2001;98:87–92. [PubMed: 11134513]
53. Meinke PT, Colletti SL, Doss G, Myers RW, Gurnett AM, Dulski PM, Darkin-Rattray SJ, Allocco JJ, Galuska S, Schmatz DM, Wyvratt MJ, Fisher MH. Synthesis of apicidin-derived quinolone derivatives: parasite-selective histone deacetylase inhibitors and antiproliferative agents. *J Med Chem* 2000;43:4919–4922. [PubMed: 11124001]
54. Colletti SL, Myers RW, Darkin-Rattray SJ, Gurnett AM, Dulski PM, Galuska S, Allocco JJ, Ayer MB, Li C, Lim J, Crumley TM, Cannova C, Schmatz DM, Wyvratt MJ, Fisher MH, Meinke PT. Broad spectrum antiprotozoal agents that inhibit histone deacetylase: structure-activity relationships of apicidin. Part 1. *Bioorg Med Chem Lett* 2001;11:107–111. [PubMed: 11206438]
55. Colletti SL, Myers RW, Darkin-Rattray SJ, Gurnett AM, Dulski PM, Galuska S, Allocco JJ, Ayer MB, Li C, Lim J, Crumley TM, Cannova C, Schmatz DM, Wyvratt MJ, Fisher MH, Meinke PT. Broad spectrum antiprotozoal agents that inhibit histone deacetylase: structure-activity relationships of apicidin. Part 2. *Bioorg Med Chem Lett* 2001;11:113–117. [PubMed: 11206439]
56. Taunton J, Collins JL, Schreiber SL. Synthesis of natural and modified trapoxins, useful reagents for exploring histone deacetylase function. *J Am Chem Soc* 1996;118:10412–10422.
57. Berst F, Ladlow M, Holmes AB. Solid-phase synthesis of apicidin A and a cyclic tetrapeptoid analogue. *Chem Commun* 2002:508–509.
58. Shivashimpi GM, Amagai S, Kato T, Nishino N, Maeda S, Nishino TG, Yoshida M. Molecular design of histone deacetylase inhibitors by aromatic ring shifting in chlamydocin framework. *Bioorg Med Chem* 2007;15:7830–7839. [PubMed: 17881232]
59. Gomez-Paloma L, Bruno I, Cini E, Khochbin S, Rodriguez M, Taddei M, Terracciano S, Sadoul K. Design and synthesis of cyclopeptide analogues of the potent histone deacetylase inhibitor FR235222. *ChemMedChem* 2007;2:1511–1519. [PubMed: 17694590]
60. Horne WS, Olsen CA, Beierle JM, Montero A, Ghadiri MR. Probing the bioactive conformation of an archetypal natural product HDAC inhibitor with conformationally homogeneous triazole-modified cyclic tetrapeptides. *Angew Chem Int Ed* 2009;48:4718–4724.
61. Ying Y, Liu Y, Byeon SR, Kim H, Luesch H, Hong J. Synthesis and activity of largazole analogues with linker and macrocycle modification. *Org Lett* 2008;10:4021–4024. [PubMed: 18707106]
62. Bowers AA, Greshock TJ, West N, Estiu G, Schreiber SL, Wiest O, Williams RM, Bradner JE. Synthesis and conformation-activity relationships of the peptide isosteres of FK228 and largazole. *J Am Chem Soc* 2009;131:2900–2905.

63. Bowers AA, West N, Newkirk TL, Troutman-Youngman AE, Schreiber SL, Wiest O, Bradner JE, Williams RM. Synthesis and histone deacetylase inhibitory activity of largazole analogs: alteration of the zinc-binding domain and macrocyclic scaffold. *Org Lett* 2009;11:1301–1304. [PubMed: 19239241]
64. Schumann F, Muller A, Kokschi M, Muller G, Sewald N. Are beta-amino acids gamma-turn mimetics? Exploring a new design principle for bioactive cyclopeptides. *J Am Chem Soc* 2000;122:12009–12010.
65. Glenn MP, Kelso MJ, Tyndall JD, Fairlie DP. Conformationally homogeneous cyclic tetrapeptides: useful new three-dimensional scaffolds. *J Am Chem Soc* 2003;125:640–641. [PubMed: 12526657]
66. Norgren AS, Buttner F, Prabpai S, Kongsaree P, Arvidsson PI. Beta2-amino acids in the design of conformationally homogeneous cyclo-peptide scaffolds. *J Org Chem* 2006;71:6814–6821. [PubMed: 16930031]
67. Montero A, Beierle JM, Olsen CA, Ghadiri MR. Design, synthesis, biological evaluation, and structural characterization of potent histone deacetylase inhibitors based on cyclic alpha/beta-tetrapeptide architectures. *J Am Chem Soc* 2009;131:3033–3041. [PubMed: 19239270]
68. Lam KS, Salmon SE, Hersch EM, Hruby VJ, Kazmierski WM, Knapp RJ. A new type of synthetic peptide library for identifying ligand-binding activity. *Nature* 1991;354:82–84. [PubMed: 1944576]
69. Yang WM, Tsai SC, Wen YD, Fejer G, Seto E. Functional domains of histone deacetylase-3. *J Biol Chem* 2002;277:9447–9454. [PubMed: 11779848]
70. Glenn MP, Kahnberg P, Boyle GM, Hansford KA, Hans D, Martyn AC, Parsons PG, Fairlie DP. Antiproliferative and phenotype-transforming antitumor agents derived from cysteine. *J Med Chem* 2004;47:2984–2994. [PubMed: 15163181]
71. Simon MD, Chu F, Racki LR, de la Cruz CC, Burlingame AL, Panning B, Narlikar GJ, Shokat KM. The site-specific installation of methyl-lysine analogs into recombinant histones. *Cell* 2007;128:1003–1012. [PubMed: 17350582]
72. Krennhrubec K, Marshall BL, Hedglin M, Verdin E, Ulrich SM. Design and evaluation of 'Linkerless' hydroxamic acids as selective HDAC8 inhibitors. *Bioorg Med Chem Lett* 2007;17:2874–2878. [PubMed: 17346959]
73. Kahnberg P, Lucke AJ, Glenn MP, Boyle GM, Tyndall JD, Parsons PG, Fairlie DP. Design, synthesis, potency, and cytoselectivity of anticancer agents derived by parallel synthesis from alpha-aminosuberic acid. *J Med Chem* 2006;49:7611–7622. [PubMed: 17181145]
74. Redman JE, Wilcoxon KM, Ghadiri MR. Automated mass spectrometric sequence determination of cyclic peptide library members. *J Comb Chem* 2003;5:33–40. [PubMed: 12523832]
75. Haggarty SJ, Koeller KM, Wong JC, Butcher RA, Schreiber SL. Multidimensional chemical genetic analysis of diversity-oriented synthesis-derived deacetylase inhibitors using cell-based assays. *Chem Biol* 2003;10:383–396. [PubMed: 12770821]
76. Haggarty SJ, Koeller KM, Wong JC, Grozinger CM, Schreiber SL. Domain-selective small-molecule inhibitor of histone deacetylase 6 (HDAC6)-mediated tubulin deacetylation. *Proc Natl Acad Sci U S A* 2003;100:4389–4394. [PubMed: 12677000]
77. Estiu G, Greenberg E, Harrison CB, Kwiatkowski NP, Mazitschek R, Bradner JE, Wiest O. Structural origin of selectivity in class II-selective histone deacetylase inhibitors. *J Med Chem* 2008;51:2898–2906. [PubMed: 18412327]
78. Suzuki T, Kouketsu A, Itoh Y, Hisakawa S, Maeda S, Yoshida M, Nakagawa H, Miyata N. Highly potent and selective histone deacetylase 6 inhibitors designed based on a small-molecular substrate. *J Med Chem* 2006;49:4809–4812. [PubMed: 16884291]
79. Itoh Y, Suzuki T, Kouketsu A, Suzuki N, Maeda S, Yoshida M, Nakagawa H, Miyata N. Design, synthesis, structure--selectivity relationship, and effect on human cancer cells of a novel series of histone deacetylase 6-selective inhibitors. *J Med Chem* 2007;50:5425–5438. [PubMed: 17929798]
80. Heltweg B, Dequiedt F, Marshall BL, Brauch C, Yoshida M, Nishino N, Verdin E, Jung M. Subtype selective substrates for histone deacetylases. *J Med Chem* 2004;47:5235–5243. [PubMed: 15456267]
81. Because the IC₅₀ values for HDAC8 were obtained using a different substrate that gave a better signal-background ratio for this enzyme, we also measured the inhibition constant for **23** against HDAC8 applying the same substrate as used for HDACs 1, 3, and 6. This IC₅₀ value was in the same

range as observed with the HDAC8 specific substrate Ac-Lys(Ac)-AMC ($IC_{50} = 343$ nM), which further confirmed the HDAC8/HDAC6 selectivity for compound **23**.

82. Kozikowski AP, Tapadar S, Luchini DN, Kim KH, Billadeau DD. Use of the nitrile oxide cycloaddition (NOC) reaction for molecular probe generation: a new class of enzyme selective histone deacetylase inhibitors (HDACIs) showing picomolar activity at HDAC6. *J Med Chem* 2008;51:4370–4373. [PubMed: 18642892]
83. Gurard-Levin ZA, Mrksich M. The activity of HDAC8 depends on local and distal sequences of its peptide substrates. *Biochemistry* 2008;47:6242–6250. [PubMed: 18470998]
84. Chou CJ, Herman D, Gottesfeld JM. Pimelic diphenylamide 106 is a slow, tight-binding inhibitor of class I histone deacetylases. *J Biol Chem* 2008;283:35402–35409. [PubMed: 18953021]
85. Wegener D, Hildmann C, Riester D, Schwienhorst A. Improved fluorogenic histone deacetylase assay for high-throughput-screening applications. *Anal Biochem* 2003;321:202–208. [PubMed: 14511685]
86. Salisbury CM, Cravatt BF. Activity-based probes for proteomic profiling of histone deacetylase complexes. *Proc Natl Acad Sci U S A* 2007;104:1171–1176. [PubMed: 17227860]
87. Salisbury CM, Cravatt BF. Optimization of activity-based probes for proteomic profiling of histone deacetylase complexes. *J Am Chem Soc* 2008;130:2184–2194. [PubMed: 18217751]
88. Lam KS, Lebl M, Krchnak V. The “One-bead-one-compound” combinatorial library method. *Chem Rev* 1997;97:411–448. [PubMed: 11848877]
89. Dartois V, Sanchez-Quesada J, Cabezas E, Chi E, Dubbelde C, Dunn C, Granja J, Gritzen C, Weinberger D, Ghadiri MR, Parr TR Jr. Systemic antibacterial activity of novel synthetic cyclic peptides. *Antimicrob Agents Chemother* 2005;49:3302–3310. [PubMed: 16048940]
90. Horne WS, Wiethoff CM, Cui C, Wilcoxon KM, Amorin M, Ghadiri MR, Nemerow GR. Antiviral cyclic D,L-alpha-peptides: targeting a general biochemical pathway in virus infections. *Bioorg Med Chem* 2005;13:5145–5153. [PubMed: 15993611]
91. Fletcher JT, Finlay JA, Callow ME, Callow JA, Ghadiri MR. A combinatorial approach to the discovery of biocidal six-residue cyclic D,L-alpha-peptides against the bacteria methicillin-resistant *Staphylococcus aureus* (MRSA) and *E. coli* and the biofouling algae *Ulva linza* and *Navicula perminuta*. *Chem Eur J* 2007;13:4008–4013.

Figure 1. HDAC inhibitors, natural products, and scaffolds. Arrows show the amide chain directionality. Scaffold **3** shows the structure of our previously developed $\alpha_3\beta$ ring type. Compound **4** is based on the optimized synthetic $\alpha_3\beta$ ring type, but contains a cysteine residue that readily allows for introduction of different Zn²⁺-coordinating moieties.

Figure 2.
Synthetic scheme and amino acids used in the first-generation library.

Figure 3.

First-generation library screening results. The library screening in 96-well plates initially provided 15 “hits” that satisfied a criteria of >75% inhibition at 10 μ M and >25% inhibition at 1 μ M against HeLa cell extract. Identified hits were then retested in duplicate and sequenced using LC–MS/MS, which confirmed six different hit structures. A) Structures of hits and approximate IC_{50} values were obtained from plots the inhibition data; the dose–response curve for apicidin (blue) is shown in each plot for comparison. B) Table showing the abundance of amino acids by position in the hit series.

aa2

aa3

aa4

Figure 4.
Amino acids included in the second-generation tetrapeptide library (525 members).

Figure 5.
Chemical structures of peptide ligands.

Figure 6.

Summary of the obtained SAR information. The shown high-resolution NMR structure of lead compound **3b** in DMSO-*d*₆ was determined previously by our group.⁶⁷ The hydrogen atoms are omitted for clarity.

Figure 7.

Western blot analysis of lysates from Jurkat cells treated with selected compounds and controls. Concentrations of compounds **10** and **23** are shown in μ M. The presence of acetylated tubulin is an indicator of HDAC6 inhibition, whereas the presence of acetylated histone H3 indicates inhibition of the class-I HDACs. Histone H3 (bottom) serves as a control for protein loading.

Table 1
Potencies of **3a-3c**, **4a-d**, apicidin, and TSA against HeLa extracts and recombinant enzymes (IC₅₀ [nM]).^a

compound	HeLa extracts		Class-I			Class-IIb	
	nuclear	cytosolic	HDAC1	HDAC3 ^b	HDAC8	HDAC6	HDAC6
3a	324±4	625±26	116±4	608±3	2,300 ^c	2,309±24	
3b	19 ^c	85±6	26±3	143±10	2,200 ^c	>10,000	
3c	<1 ^c	3±1.5	2±1.4	18±3	133 ^c	31±2	
4a	54 ^c	54±5	(20)	62±7	(4,920)	>10,000	
4b	ND	ND	>10,000	>10,000	>10,000	>10,000	
4c	ND	ND	(4,840)	(7,080)	(6,050)	>10,000	
4d	ND	ND	>10,000	>10,000	(9,700)	>10,000	
1a apicidin	22±6	43±8	22±4	29±4	755±19	>10,000	
TSA^d	3±1.3	3±1.0	3.3±1.5	11±1.4	25±3	6±1.9	

^a IC₅₀ values are means of at least two experiments performed in duplicate unless otherwise noted. Values in parentheses are from a single assay performed in duplicate.
^b In complex with NCoR2.
^c From our previous report.⁶⁷
^d TSA (Trichostatin A) was included as a positive control inhibitor in the assays with HDAC6 and HDAC8, since apicidin is not a potent inhibitor of these enzymes. ND = not determined.

Table 2

IC₅₀ values [nM] of purified compounds against HeLa nuclear extract and recombinant enzymes.^a

compound	HeLa nuclear extract	Class-I			Class-IIb
		HDAC1	HDAC3 ^b	HDAC8	HDAC6
8a c[Asu-Nal-β ³ Leu-Ala]	205±5	198±6	990±22	ND	4,900±66
8b c[Aoda-Nal-β ³ Leu-Ala]	17±2	8±1.1	32±1.2	ND	>10,000
9 c[Asu-Nal-β ³ Trp-Phe]	1,040±11	456±18	1,668±28	ND	(8,000)
10 c[Asu-Nal-β ³ Leu-Phe]	253±4	68±3	686±22	526±11	5,800±35
11 c[Asu-Nal-β ³ Trp-Aib]	1,010±18	(751)	(2,990)	(2,670)	(3,700)
14 c[Asu-Nal-β ³ Leu-Aib]	499±17	136±1	970±11	(870)	(7,000)
15 c[Aoda-Trp-β ³ Leu-Lys(Ac)]	ND	42±5	54±5	150±9	>10,000
16 c[Aoda-Trp-β ³ Leu-Aoda]	ND	152±19	258±13	1,400±40	>10,000
17 c[Asu-Nal-β ³ Leu-Arg]	ND	(178)	262±3	(607)	1,400±23
18 c[Asu-Nal-β ³ Ser-Arg]	ND	ND	1,090±10	ND	2,320±19
19 c[Asu-Nal-β ³ Tyr-Arg]	ND	ND	694±4	(1,400)	1,080±21
20 c[Asu-Nal-β ³ Tyr-Lys(Ac)]	ND	288±4	1,040±22	(1,380)	4,400±32
21 c[Asu-Nal-β ³ Tyr-Phe(F ₅)]	ND	(~1,000)	3,630±15	(6,700)	>10,000
22 c[Asu-Asp-β ³ Tyr-Arg]	ND	>10,000	>10,000	ND	>10,000
23 c[Asu(NHOH)-Asp-β ³ Tyr-Arg]	ND	122±15	164±4	244±9	39±3
24 c[Aoda-Trp-β ³ Leu-Phe] ^c	ND	ND	ND	ND	ND
25 c[Asu(NHOH)-Trp-β ³ Leu-Phe]	ND	ND	31±5	ND	70±6
26 c[Asu-Nal-β ³ Leu-Lys]	ND	ND	242±5	ND	1,120±11
27 c[Asu-Nal-β ³ Leu-Lys(Ac)]	ND	56±4	193±8	1,000±17	1,670±19
28 c[Cys(Pa)-Trp-β ³ Leu-Lys(Ac)]	ND	ND	>10,000	7,040±51	>10,000
1a apicidin	22±6	22±4	29±4	755±19	>10,000
TSA	3±1.3	3.3±1.5	11±1.4	25±3	6±1.9

^aIC₅₀ values are means of at least two experiments performed in duplicate. Values in parentheses are from a single assay performed at least in duplicate. ND = not determined. Pa = 3-propanoic acid (see Figure 1 for structure).

^bIn complex with NCoR2.

^cThis compound was too hydrophobic for assaying.

Table 3

GI₅₀ values [μ M] for selected compounds against various cancer cells.^a

compound	HeLa	MCF-7	Jurkat	K-562	KYO-1
vinblastine	0.06	~10	<0.01	0.3	<0.1
1a apicidin	3	7	4	0.9	2.5
3b	3.5 ^b	>20 ^b	ND	2 ^b	10.5 ^b
3c	5.6 ^b	0.6 ^b	1.7	1.6 ^b	0.8 ^b
8b	18	ND	0.3	30	43
10	>20	>20	>20	>20	>20
15	>20	>20	>20	ND	ND
23	9	>20	>20	ND	ND
25	ND	ND	1.3	1.9	1.9

^a HeLa (cervical cancer), MCF-7 (breast cancer), Jurkat (T-cell leukemia), K-562 and KYO-1 (chronic myeloid leukemia).

^b From our previous report.⁶⁷ ND = not determined.

Table 4

Data for resynthesized peptides.

compound	HPLC _{230nm}	ESI-TOF HRMS calcd./found (<i>m/z</i>)
4a	99%	608.2883/608.2893 ^a
4b	95%	594.2721/594.2721 ^a
4c	96%	582.2357/582.2348 ^a
4d	90%	568.2200/568.2198 ^a
8a	99%	589.2997/589.2996 ^a
8b	99%	579.3541/579.3537 ^b
9	90%	738.3268/738.3280 ^a
10	99%	665.3310/665.3298 ^a
11	95%	654.3286/654.3285 ^b
14	95%	603.3153/603.3197 ^a
15	99%	689.3997/689.3992 ^a
16	99%	702.4201/702.4197 ^a
17	99%	652.3812/652.3814 ^b
18	96%	626.3297/626.3300 ^b
19	99%	702.3610/702.3617 ^b
20	99%	716.3654/716.3658 ^b
21	95%	783.2812/783.2821 ^b
22 ^c	95%	620.3039/620.3027 ^b
23 ^c	90%	635.3148/635.3147 ^b
24 ^c	95%	644.3806/644.3794 ^b
25	95%	647.3557/647.3552 ^b
26 ^c	95%	624.3756/624.3759 ^b
27 ^c	92%	666.3861/666.3867 ^b
28	95%	681.3041/681.3039 ^a

^a [M+Na]⁺;^b [M+H]⁺;^c ¹H NMR spectra are included in the Supporting Information.